Abstract
The food enzyme glucan 1,4‐α‐glucosidase (4‐α‐D‐glucan α‐glucohydrolase; EC 3.2.1.3) is produced with the non‐genetically modified Aspergillus niger strain AN‐SHGA‐100 by Suntaq International Limited. The description of the food enzyme manufacturing process provided by the applicant refers to a pectinase and not to the food enzyme under assessment. The food enzyme glucan 1,4‐α‐glucosidase was considered free from viable cells of the production organism. It is intended to be used in seven food manufacturing processes. Since residual amounts of food enzyme–Total Organic Solids (TOS) are removed in two processes, dietary exposure was calculated for the remaining five processes. It was calculated to be up to 26.829 mg TOS/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90‐day oral toxicity study in rats with the food enzyme glucan 1,4‐α‐glucosidase. The Panel identified a no observed adverse effect level of 2000 mg TOS/kg bw per day, the highest dose tested, which when compared with the estimated dietary exposure, resulted margins of exposure (MoEs) of 95, 75, 107, 133, 337 and 429 for infants, toddlers, children, adolescents, adults and the elderly, respectively. A search for the homology of the amino acid sequence of the glucan 1,4‐α‐glucosidase to known allergens was made and a match with one respiratory allergen was found. The Panel considered that a risk of allergic reactions upon dietary exposure to this food enzyme cannot be excluded, but that the likelihood is low. The Panel could not conclude on the safety of this food enzyme glucan 1,4‐α‐glucosidase produced with the non‐GM A. niger strain AN‐SHGA‐100, because the description of the manufacturing process corresponds to a different enzyme. In addition, the MoEs are insufficient to exclude safety concerns for infants, toddlers, children and adolescents.
Keywords: 4‐α‐D‐glucan α‐glucohydrolase; Aspergillus niger; EC 3.2.1.3; EFSA‐Q‐2023‐00228; food enzyme; glucan‐1,4‐α‐glucosidase; glucoamylase; non‐genetically modified microorganism
1. INTRODUCTION
Article 3 of the Regulation (EC) No 1332/2008 1 provides definition for ‘food enzyme’ and ‘food enzyme preparation’.
‘Food enzyme’ means a product obtained from plants, animals or microorganisms or products thereof including a product obtained by a fermentation process using microorganisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods.
‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution.
Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No 1332/2008 on food enzymes came into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No 1331/2008 2 established the European Union (EU) procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:
it does not pose a safety concern to the health of the consumer at the level of use proposed;
there is a reasonable technological need;
its use does not mislead the consumer.
All food enzymes currently on the EU market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and approval via an EU Community list.
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background as provided by the European Commission
Only food enzymes included in the Union list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7(2) of Regulation (EC) No 1332/20081 on food enzymes.
Five applications have been introduced by the company “Amano Enzyme Inc.” and the Association of Manufacturers and Formulators of Enzyme Products (AMFEP) for the authorisation of the food enzymes Ribonuclease P from Penicillium citrinum (strain AE‐RP), Glutaminase from Bacillus amyloliquefaciens (strain AE‐GT); Oryzin from Aspergillus melleus (strain AE‐P); Triacylglycerol lipase from Candida rugosa (strain AE‐LAY) and Glucoamylase from Aspergillus niger respectively.
Following the requirements of Article 12.1 of Regulation (EC) No 234/2011 3 implementing Regulation (EC) No 1331/2008,2 the Commission has verified that the six applications fall within the scope of the food enzyme Regulation and contains all the elements required under Chapter II of that Regulation.
1.1.2. Terms of Reference
The European Commission requests the European Food Safety Authority to carry out the safety assessments on the food enzymes Ribonuclease P from Penicillium citrinum (strain AE‐RP), Glutaminase from Bacillus amyloliquefaciens (strain AE‐GT); Oryzin from Aspergillus melleus (strain AE‐P); Triacylglycerol lipase from Candida rugosa (strain AE‐LAY) and Glucoamylase from Aspergillus niger in accordance with Article 17.3 of Regulation (EC) No 1332/20081 on food enzymes.
1.2. Interpretation of the Terms of Reference
The present scientific opinion addresses the European Commission's request to carry out the safety assessment of food enzyme glucoamylase from Aspergillus niger submitted by AMFEP.
The application was submitted initially as a joint dossier 4 and identified as the EFSA‐Q‐2015‐00292. During a meeting between EFSA, the European Commission and the AMFEP, 5 it was agreed that joint dossiers will be split into individual data packages.
The current opinion addresses one data package originating from the joint dossier EFSA‐Q‐2015‐00292. This data package is identified as EFSA‐Q‐2023‐00228 and concerns the food enzyme glucan 1,4‐α‐glucosidase produced with the Aspergillus niger strain AN‐SHGA‐100 and submitted by Suntaq International Limited.
2. DATA AND METHODOLOGIES
2.1. Data
The applicant has submitted a dossier in support of the application for authorisation of the food enzyme glucoamylase from Aspergillus niger strain CCTCC M 2023310.
Additional information, requested from the applicant during the assessment process on 24 November 2023 and 12 June 2026, was received on 21 May 2024 and 10 September 2026, respectively (see ‘Section 5’).
2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA ‘Guidance on transparency in the scientific aspects of risk assessment’ (EFSA, 2009a) and following the relevant guidance documents of the EFSA Scientific Committee.
The ‘Guidance on the submission of a dossier on food enzymes for safety evaluation’ (EFSA CEF, 2009b) as well as the ‘Statement on characterisation of microorganisms used for the production of food enzymes’ (EFSA CEP Panel, 2019) have been followed for the evaluation of the application. Additional information was requested in accordance with the updated ‘Scientific Guidance for the submission of dossiers on food enzymes’ (EFSA CEP Panel, 2021) and the guidance on the ‘Food manufacturing processes and technical data used in the exposure assessment of food enzymes’ (EFSA CEP Panel, 2023).
3. ASSESSMENT
| IUBMB nomenclature | Glucan 1,4‐α‐glucosidase |
| Systematic name | 4‐α‐D‐glucan glucohydrolase |
| Synonyms | Glucoamylase; amyloglucosidase |
| IUBMB No | EC 3.2.1.3 |
| CAS No | 9032‐08‐0 |
| EINECS No | 232‐877‐2 |
Glucan 1,4‐α‐glucosidases catalyse the hydrolytic release of terminal α‐1,4‐linked D‐glucose residues successively from the non‐reducing ends of amylose and amylopectin.
The food enzyme under assessment is intended to be used in seven food manufacturing processes as defined in the EFSA guidance (EFSA CEP Panel, 2023): processing of cereals and other grains for the production of 1) baked products, 2) brewed products, 3) glucose syrups and other starch hydrolysates and 4) distilled alcohol; processing of fruits and vegetables for the production of 5) juices and 6) fruit and vegetable products other than juices; 7) processing of plant‐ and fungal‐derived products for the production of plant‐based analogues of milk and milk products.
3.1. Source of the food enzyme
The glucan 1,4‐α‐glucosidase is produced with the non‐genetically modified filamentous fungus Aspergillus niger strain AN‐SHGA‐100, which is deposited as Aspergillus sp. at the China Centre for Type Culture Collections (CCTCC, China) with the deposition number ■■■■■. 6 The production strain was identified as A. niger by whole genome sequence analysis, showing an average nucleotide identity of 99.4% with the reference strain A. niger CBS 513.88. 7
The production strain A. niger AN‐SHGA‐100 was derived from the parental strain ■■■■■ ■■■■■. 8
A WGS search 9 identified that the genome contains ■■■■■ ■■■■■ None of these compounds is considered of concern by the Panel. The search also revealed 100% similarity with the ■■■■■ ■■■■■, which is not further investigated.
3.2. Production of the food enzyme
The food manufacturing process provided by the applicant is for a pectinase preparation from A. niger strain AN‐SHGA‐100 (■■■■■. 10 However, the Panel notes that the food enzyme under assessment is a glucan 1,4‐α‐glucosidase produced from A. niger strain AN‐SHGA‐100 (■■■■■). Consequently, the Panel is not in the position to evaluate the manufacturing process for the food enzyme under assessment.
3.3. Characteristics of the food enzyme
3.3.1. Properties of the food enzyme
The glucan 1,4‐α‐glucosidase is composed of ■■■■■ amino acids 11 and the molecular mass of the mature protein, calculated from the amino acid sequence, is ■■■■■ kDa. 12 The food enzyme was analysed by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis. 13 A consistent protein pattern was observed across all batches.
No other enzyme activities were reported. 14
The determination of glucan 1,4‐α‐glucosidase activity is based on the hydrolysis of ■■■■■ (reaction conditions: ■■■■■). The release of ■■■■■ is determined by a titrimetric method. Enzyme activity is expressed in Units (U)/g or mL. 15
The food enzyme has a temperature optimum around 70°C (■■■■■) and a pH optimum between 3.5 and 5.5 (■■■■■). Thermostability was tested by pre‐incubation of the food enzyme for 15 min at different temperatures. Enzyme activity decreased above 40°C, showing no residual activity above 80°C. 16
3.3.2. Chemical parameters
Data were provided for three batches of the food enzyme intended for commercialisation, among which batch 3 was also used for the toxicological tests (Table 1). 17 The mean Total Organic Solids (TOS) of the three food enzyme batches for commercialisation was 91.3% and the mean enzyme activity/TOS ratio was 399.8 U/mg TOS.
TABLE 1.
Composition of the food enzyme.
| Parameters | Batches | |||
|---|---|---|---|---|
| Unit | 1 | 2 | 3 a | |
| Glucan 1,4‐α‐glucosidase activity | U/g b | 361,640 | 323,564 | 410,316 |
| Protein | % | 56.9 | NA c | 67.8 |
| Ash | % | 1.3 | 1.7 | 1.4 |
| Water | % | 7.1 | 7.2 | 7.1 |
| Total Organic Solids (TOS) d | % | 91.4 | 91.1 | 91.5 |
| Glucan 1,4‐α‐glucosidase /TOS ratio | U/mg TOS | 395.7 | 355.2 | 448.4 |
Batch used for the toxicological studies.
NA: not analysed.
UNIT: U/g (see Section 3.3.1).
TOS calculated as 100% – % water – % ash.
3.3.3. Purity
The lead content in all batches was below 5 mg/kg 18 which complies with the specification for lead as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). In addition, cadmium and mercury contents were below the limits of quantification (LoQs) of the employed methods. Arsenic content analysed in two batches intended for commercialisation was 0.530 and 0.869 mg/kg, respectively. 19 The Panel considered these concentrations as not of concern. The food enzyme complies with the microbiological criteria for total coliforms, Escherichia coli and Salmonella, as laid down in the general specifications for enzymes used in food processing (FAO/WHO, 2006). 20 No antimicrobial activity was detected in any of the tested batches. 21
Strains of Aspergillus species, in common with most filamentous fungi, have the capacity to produce a range of secondary metabolites (Frisvad et al., 2018). The presence of aflatoxin B1, B2, G1 and G2, deoxynivalenol (DON), fumonisin B1 and B2, ochratoxin A, sterigmatocystin, T2‐toxin and HT2‐toxin and zearalenone was examined in two food enzyme batches. All were below the LoQ of the applied analytical methods, except for DON (90 μg/kg) and the sum of fumonisins B1 and B2 (800 μg/kg) in the batch produced for toxicological studies, and zearalenone (22 μg/kg) in another batch. 22 , 23
Using the highest estimated dietary exposure of 26.829 mg TOS/kg body weight (bw) per day as the reference (see Section 3.5.2), the concentration of DON, fumonisins and zearalenone in the food enzyme batches corresponds to 2.64, 23.5 and 0.65 ng/kg bw per day in the regular diet of consumers, respectively. They are several orders of magnitude lower than the tolerable daily intake (TDI) for DON (1 μg/kg bw per day, EFSA CONTAM Panel, 2017), fumonisins (1 μg/kg bw per day, EFSA CONTAM Panel, 2018) and zearalenone (0.25 μg/kg bw per day, EFSA CONTAM Panel, 2011), respectively.
The Panel considered that the information provided on the purity of the food enzyme was sufficient.
3.3.4. Viable cells of the production strain
The absence of viable cells of the production strain in the food enzyme was demonstrated in four independent batches analysed in triplicate (1 powder batch and 3 liquid batches). ■■■■■. No colonies were detected. A positive control was included. 24
3.4. Toxicological data
A battery of toxicological tests including a bacterial reverse mutation test (Ames test), an in vitro mammalian cell micronucleus test and a repeated dose 90‐day oral toxicity study in rats has been provided.
The batch 3 (Table 1) used in these studies is one of the batches intended for commercialisation and has a similar enzyme activity/TOS ratio to the other batches and thus is considered suitable as a test item.
3.4.1. Genotoxicity
3.4.1.1. Bacterial reverse mutation test
A bacterial reverse mutation test (Ames test) was performed according to the Organisation for Economic Co‐operation and Development (OECD) Test Guideline 471 (OECD, 2020) and following good laboratory practice (GLP). 25 Five strains of Salmonella Typhimurium (TA98, TA100, TA102, TA1535 and TA1537) were used with or without metabolic activation (S9‐mix), applying the pre‐incubation and standard plate incorporation method.
Two experiments were carried out in triplicate, using five concentrations of the food enzyme of 50, 158, 500, 1583 and 5000 μg TOS/plate.
No cytotoxicity was observed at any concentration of the test substance. Upon treatment with the food enzyme, there was no biologically relevant increase in the number of revertant colonies above the control values in any strain tested, with or without S9‐mix.
The Panel concluded that the food enzyme did not induce gene mutations under the test conditions applied in this study.
3.4.1.2. In vitro mammalian cell micronucleus test
The in vitro mammalian cell micronucleus test was carried out according to OECD Test Guideline 487 (OECD, 2016) and following GLP. 26 An experiment was performed with duplicate cultures of Chinese Hamster Ovary (CHO‐K1) cell line. The cell cultures were treated with the food enzyme with or without metabolic activation (S9‐mix).
On the basis of the results of the dose range‐finding test, in the main experiment, cells were exposed to the food enzyme and scored for the frequency of binucleated cells with micronuclei (MNBN) at concentrations of 1250, 2500 and 5000 μg TOS/mL in a short‐term treatment (4‐h exposure and 20‐h recovery period) either with or without S9‐mix and in a long‐term treatment (24‐h exposure and 20‐h recovery period) without S9‐mix.
No cytotoxicity (based on Cytokinesis Block Proliferative Index (CBPI)) was seen either in the short‐term treatment with and without S9‐mix or in the long‐term treatment. The frequency of MNBN was not statistically significantly different to the negative controls at any concentration tested.
The Panel concluded that the food enzyme did not induce an increase in the frequency of MNBN under the test conditions applied in this study.
3.4.2. Repeated dose 90‐day oral toxicity study in rodents
The repeated dose 90‐day oral toxicity study was performed under GLP and according to the OECD Test Guideline 408 (OECD, 2018). 27 , 28
Groups of 10 male and 10 female Sprague–Dawley (Crl:CD(SD)) rats received the food enzyme by gavage in doses of 500, 1000 or 2000 mg TOS/kg bw per day. Controls received the vehicle (ultrapure water type 1).
No mortality was observed.
Haematological investigations revealed a statistically significant decrease in red blood cells (RBC, −5% and −2%) and in mean corpuscular haemoglobin concentration (MCHC, −3% both) in mid‐ and high‐dose males, a decrease in haemoglobin (Hgb) concentration in low‐ and mid‐dose males (−6% and −5%), an increase in neutrophil count (Neu) in low‐ and high‐dose males (+48% and +46%), a decrease in Neu (−41%) and in monocyte count (Mon, −62%) in high‐dose females, an increase in reticulocyte count (Ret, +35%) and in platelet count (Plt, +18%) in mid‐dose males, a decrease in prothrombin time (PT) in mid‐ and high‐dose females (−8% both), a decrease in activated partial thromboplastin time (APTT) in low‐, mid‐ and high‐dose females (−13%, −12% and −11%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (all except of Neu), there was no consistency between the change in males and females (Neu), there was no dose–response relationship (RBC, MCHC, Hgb, Neu in males, Ret, PT, APTT, Plt), there were no changes in other relevant parameters (other white blood cell parameters), there were no histopathological changes in bone marrow and the changes were within the historical control values (except for Ret in males).
Clinical chemistry investigations revealed a statistically significant increase in plasma glucose (+29% and +37%) and high‐density lipoprotein (HDL, +29% and +54%) in high‐dose males and in high‐dose females, an increase in plasma cholesterol (Chol, +36%), low density lipoprotein (LDL, +31%), aspartate aminotransferase (AST, +86%) and sodium concentration (Na, +1%) in high‐dose females, an increase in blood urea nitrogen (BUN, +20% and +27%) and a decrease in calcium concentration (Ca, −7% and −0.2%) in mid‐ and high‐dose males, an increase in total proteins (TP) in mid‐ and high‐dose males (+17% and +21%) and in mid‐ and high‐dose females (+8% and +15%), an increase in albumin in mid‐ and high‐dose males (+21% and +22%) and in mid‐ and high‐dose females (+25% and +32%), an increase in globulin (Glo) in mid‐ and high‐dose males (+15% and +20%) and in high‐dose females (+11%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (Chol, LDL, AST, Na, BUN, Ca), there was no dose–response relationship (Ca), there were no changes in other relevant parameters (creatinine, other liver enzymes, other electrolytes), there were no histopathological changes in liver and kidneys and the changes were within the historical control values (except of AST, HDL, LDL in females, TP in males and females).
Statistically significant changes in hormone levels included an increase in tri‐iodothyronine (T3) levels in high‐dose males (+50%), a decrease in thyroxine (T4) in low‐dose females (−25%) and an increase in thyroid‐stimulating hormone (TSH) in low‐dose females (+150%). The Panel considered the changes as not toxicologically relevant, as they were only observed in one sex (all parameters), there was no dose–response relationship (T4, TSH) and there were no histopathological or dose‐related weight changes in the thyroid and pituitary glands (except of the increased relative pituitary gland weight in low‐dose males, +5%) and the changes were within the historical control values (except of T3).
No toxicologically relevant or other statistically significant differences from controls were reported.
The Panel identified a no observed adverse effect level (NOAEL) of 2000 mg TOS/kg bw per day, the highest dose tested.
3.4.3. Allergenicity
The allergenicity assessment considered only the food enzyme and not additives, carriers or other excipients that may be used in the final formulation.
The potential allergenicity of the glucan 1,4‐α‐glucosidase produced with Aspergillus niger strain AN‐SHGA‐100 was assessed by comparing its amino acid sequence with those of known allergens as described in the EFSA GMO Scientific Opinion (EFSA GMO Panel, 2010). Using higher than 35% identity in a sliding window of 80 amino acids as the criterion, a match with one respiratory allergen was found in the AllergenOnline database. 29
The matching allergen was Sch c 1 (67.5% sequence identity), a glucan 1,4‐α‐glucosidase from Schizophyllum commune.
No reports on oral or respiratory sensitisation or elicitation reactions of the glucan 1,4‐α‐glucosidase under assessment have been published. 30
Glucan 1,4‐α‐glucosidase from S. commune is known as an occupational respiratory allergen associated with baker's asthma (Simonis et al., 2014; Toyotome et al., 2014). Several studies have shown that individuals respiratorily sensitised to a food enzyme are usually able to ingest the corresponding enzyme without acquiring clinical symptoms of food allergy (Armentia et al., 2009; Cullinan et al., 1997; Poulsen, 2004). Adverse reactions upon dietary exposure to glucan 1,4‐α‐glucosidases in individuals sensitised through the respiratory route have not been reported.
The Panel considered that the results of the sequence homology search and the available literature do not indicate a risk of allergic reactions upon dietary exposure to the glucan 1,4‐α‐glucosidase under assessment.
The production strain belongs to the Aspergillus genus, which is known to cause respiratory allergy (Kurup et al., 2000; Shen & Han, 1998; Vermani et al., 2015). Allergic reactions upon dietary exposure have been observed, but are rare (Xing et al., 2022). The biomass is removed during the production process; however, allergenic proteins of the production strain can be released into the culture medium from which the food enzyme is obtained.
■■■■■ and ■■■■■, known sources of allergens, are present in the culture medium. During the fermentation process, these products will mostly be degraded and utilised by the production strain.
Taken together, concerning the potential allergic reactions due to the production strain and the raw materials in the culture medium, the Panel considered that residual amounts of allergenic proteins could be present in the food enzyme. Taking into account the level of dietary exposure (see Section 3.5), this would result in minute amounts in the final foods, from which allergic reactions are usually not expected.
In conclusion, when used for the production of distilled alcohol, the Panel considered that a risk of allergic reactions upon dietary exposure can be excluded. For the remaining intended uses, the risk of allergic reactions upon dietary exposure to this glucan 1,4‐α‐glucosidase cannot be excluded, but the likelihood is low.
3.5. Dietary exposure
3.5.1. Intended use of the food enzyme
The food enzyme is intended to be used in seven food manufacturing processes at the recommended use levels summarised in Table 2.
TABLE 2.
Intended uses and recommended use levels of the food enzyme as provided by the applicant. 31
| Food manufacturing process a | Raw material (RM) | Maximum recommended use level (mg TOS/kg RM) b , c |
|---|---|---|
| Processing of cereals and other grains | ||
|
Flour | 268.3 |
|
Wort | 1012.0 |
|
Starch | 1012.0 |
|
Starch | 1012.0 |
| Processing of fruits and vegetables | ||
|
Fruit and vegetables | 74.6 |
|
Fruit and vegetables | 1240.2 |
| Processing of plant‐ and fungal‐derived products | ||
|
Cereals, legumes, oilseeds, nuts, etc. | 1012.0 |
The glucan 1,4‐α‐glucosidase catalyses the hydrolysis of starch in a variety of raw materials to release glucose. It is used to increase the amount of fermentable sugars or to enhance sweetness.
In the production of baked products, the food enzyme is added to flour during dough preparation. 33 The food enzyme–TOS remain in the final bakery foods.
In the production of brewed products, the food enzyme is added to wort during fermentation. 34 The food enzyme–TOS remain in the brewed products.
In the production of glucose syrups and other starch hydrolysates, the food enzyme is added to starch during the saccharification. 35 The Panel considers that the food enzyme–TOS are removed from glucose syrups and other starch hydrolysates (EFSA CEP Panel, 2023).
In the production of distilled alcohol, the food enzyme is added to cereals during the saccharification and the fermentation. 36 The food enzyme–TOS are not carried over into the distilled alcohols (EFSA CEP Panel, 2023).
In the production of juices, the food enzyme may be added to the crushed fruits and vegetables during mash treatment or to the raw juice during clarification. 37 The food enzyme–TOS remain in the juices.
In the production of fruit and vegetable products other than juices, the food enzyme is added to the crushed fruits and vegetables during the mash treatment. 38 The food enzyme–TOS remain in the final foods.
In the production of plant‐based analogues of milk and milk products, the food enzyme is added to the cereal slurry. 39 The food enzyme–TOS remain in the final foods.
Based on data provided on thermostability (see Section 3.3.1) and the downstream processing within the respective food manufacturing processes, the Panel considered that the enzyme is inactivated during the production of plant‐based analogues of milk and milk products. However, it may remain in its active form in the other food manufacturing processes listed in Table 2 in which the food enzyme‐TOS remain, depending on the heat treatment conditions.
3.5.2. Dietary exposure estimation
In accordance with the guidance document (EFSA CEP Panel, 2021), dietary exposure was calculated for the five food manufacturing processes where the food enzyme–TOS remain in the final foods.
Chronic exposure to the food enzyme–TOS was calculated using the FEIM webtool 40 by combining the maximum recommended use level with individual consumption data (EFSA CEP Panel, 2021). The estimation involved selection of relevant food categories and application of technical conversion factors (EFSA CEP Panel, 2023).
Table 3 provides an overview of the derived exposure estimates across all surveys. Detailed mean and 95th percentile exposure to the food enzyme–TOS per age class, country and survey, as well as contribution from each FoodEx category to the total dietary exposure are reported in Appendix A – Tables 1 and 2. For the present assessment, food consumption data were available from 51 dietary surveys (covering infants, toddlers, children, adolescents, adults and the elderly), carried out in 27 European countries (Appendix B). The highest dietary exposure was estimated to be 26.829 mg TOS/kg bw per day in toddlers at the 95th percentile.
TABLE 3.
Summary of the estimated dietary exposure to the food enzyme–TOS in six population groups.
| Population group | Estimated exposure (mg TOS/kg body weight per day) | |||||
|---|---|---|---|---|---|---|
| Infants | Toddlers | Children | Adolescents | Adults | The elderly | |
| Age range | 4–11 months | 12–35 months | 3–9 years | 10–17 years | 18–64 years | ≥65 years |
| Min–max mean (number of surveys) | 0.847–16.700 (14) | 1.831–9.597 (17) | 1.612–6.110 (21) | 0.786–4.504 (23) | 0.658–2.205 (23) | 0.451–1.922 (25) |
| Min–max 95th percentile (number of surveys) | 2.315–20.999 (13) | 4.863–26.829 (16) | 3.840–18.754 (21) | 2.013–15.040 (22) | 1.543–5.926 (23) | 1.146–4.658 (24) |
3.5.3. Uncertainty analysis
In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure assessment (EFSA, 2006), the following sources of uncertainties have been considered and are summarised in Table 4.
TABLE 4.
Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate.
| Sources of uncertainties | Direction of impact |
|---|---|
| Model input data | |
| Consumption data: different methodologies/representativeness/underreporting/misreporting/no portion size standard | +/− |
| Use of data from food consumption surveys of a few days to estimate long‐term (chronic) exposure for high percentiles (95th percentile) | + |
| Possible national differences in categorisation and classification of food | +/− |
| Model assumptions and factors | |
| Exposure to food enzyme–TOS always calculated based on the recommended maximum use level | + |
| Selection of broad FoodEx categories for the exposure assessment | + |
| Use of recipe fractions to disaggregate FoodEx categories | +/− |
| Use of technical factors in the exposure model | +/− |
|
Exclusion of two processes from the exposure estimation: ‐ Production of distilled alcohol ‐ Production of glucose syrups and other starch hydrolysates |
− |
Note: +, uncertainty with potential to cause overestimation of exposure. –, uncertainty with potential to cause underestimation of exposure.
The conservative approach applied to estimate the dietary exposure to the food enzyme–TOS, in particular assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led to an overestimation of the exposure.
The exclusion of two food manufacturing processes from the exposure estimation was based on > 99% of TOS removal. This is not expected to impact the overall estimate derived.
3.6. Margin of exposure
A comparison of the NOAEL (2000 mg TOS/kg bw per day) identified from the 90‐day rat study with the derived exposure estimates of 0.451–16.700 mg TOS/kg bw per day at the mean and from 1.146 to 26.829 mg TOS/kg bw per day at the 95th percentile resulted in margins of exposure (MoEs) for infants, toddlers, children, adolescents, adults and the elderly of 95, 75, 107, 133, 337 and 429, respectively.
4. CONCLUSIONS
The Panel could not conclude on the safety of the food enzyme glucan 1,4‐α‐glucosidase produced with the non‐GM A. niger strain AN‐SHGA‐100, because the description of the manufacturing process corresponds to a pectinase. In addition, the MoEs are insufficient to exclude safety concerns for infants, toddlers, children and adolescents.
5. DOCUMENTATION AS PROVIDED TO EFSA
Request for the authorisation of glucoamylase produced by Aspergillus niger CCTCC M 2023310 for use as a food processing aid. March 2023. Submitted by Suntaq International Limited.
Additional information. May 2024. Submitted by Suntaq International Limited.
Additional information. September 2026. Submitted by Suntaq International Limited.
ABBREVIATIONS
- AMFEP
Association of Manufacturers and Formulators of Enzyme Products
- APTT
activated partial thromboplastin time
- BUN
blood urea nitrogen
- bw
body weight
- CAS
Chemical Abstracts Service
- CBPI
Cytokinesis Block Proliferative Index
- CEP
EFSA Panel on Food Contact Materials, Enzymes and Processing Aids
- EC
European Commission
- EINECS
European Inventory of Existing Commercial Chemical Substances
- EU
European Union
- FAO
Food and Agricultural Organization of the United Nations
- GLP
Good Laboratory Practice
- GMO
genetically modified organism
- HDL
high‐density lipoprotein
- IUBMB
International Union of Biochemistry and Molecular Biology
- JECFA
Joint FAO/WHO Expert Committee on Food Additives
- kDa
kiloDalton
- LDL
low‐density lipoprotein
- LoQ
limit of quantification
- MCHC
mean corpuscular haemoglobin concentration
- MNBN
bi‐nucleated cells with micronuclei
- MoE
margin of exposure
- OECD
Organisation for Economic Cooperation and Development
- PCR
polymerase chain reaction
- PT
prothrombin time
- RBC
red blood cells
- TDI
tolerable daily intake
- TSH
thyroid stimulating hormone
- TOS
Total Organic Solids
- TP
total protein
- WGS
whole genome sequencing
- WHO
World Health Organization
AUTHOR CONTRIBUTIONS
Under Regulation 178/2002, the Scientific Panel is the author of the scientific output. Contributions include: Working Groups who provide the draft assessment which is reviewed and adopted by the Panel; EFSA staff members who provide scientific support including inter alia data collection and analysis and literature searching; and other contributors such as staff of national food safety agencies, EFSA trainees and interim staff members who have contributed meaningfully to the work.
REQUESTOR
European Commission
QUESTION NUMBER
EFSA‐Q‐2023‐00228
COPYRIGHT FOR NON‐EFSA CONTENT
EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source.
LEGAL NOTICE
The full opinion will be published in accordance with Article 12 of Regulation (EC) No 1331/2008 once the decision on confidentiality will be received from the European Commission.
Supporting information
APPENDIX A Dietary exposure estimates to the food enzyme—TOS in details
ACKNOWLEDGEMENTS
The Panel wishes to thank the following for the support provided to this scientific output: Andrew Chesson, Pier Sandro Cocconcelli, Eleonora Marini and Francesco Pesce.
APPENDIX A. Dietary exposure estimates to the food enzyme–TOS in details
Appendix A can be found in the online version of this output (in the ‘Supporting Information’ section). The file contains two sheets, corresponding to two tables.
Table 1: Average and 95th percentile exposure to the food enzyme–TOS per age class, country and survey.
Table 2: Contribution of food categories to the dietary exposure to the food enzyme–TOS per age class, country and survey.
APPENDIX B. Population groups considered for the exposure assessment
| Population | Age range | Countries with food consumption surveys covering more than 1 day |
|---|---|---|
| Infants | From 16 weeks on up to and including 11 months of age | Bulgaria, Croatia, Cyprus, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Poland, Portugal, Slovenia, Spain |
| Toddlers | From 12 months up to and including 35 months of age | Belgium, Bulgaria, Croatia, Cyprus, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Latvia, Montenegro*, Netherlands, Poland, Portugal, Republic of North Macedonia*, Serbia*, Slovenia, Spain |
| Children | From 36 months up to and including 9 years of age | Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Montenegro*, Netherlands, Poland, Portugal, Republic of North Macedonia*, Serbia*, Spain, Sweden |
| Adolescents | From 10 years up to and including 17 years of age | Austria, Belgium, Bosnia and Herzegovina*, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Montenegro*, Netherlands, Poland, Portugal, Romania, Serbia*, Slovenia, Spain, Sweden |
| Adults | From 18 years up to and including 64 years of age | Austria, Belgium, Bosnia and Herzegovina*, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Montenegro*, Netherlands, Poland, Portugal, Romania, Serbia*, Slovenia, Spain, Sweden |
| The elderly a | From 65 years of age and older | Austria, Belgium, Croatia, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Montenegro*, Netherlands, Poland, Portugal, Romania, Serbia*, Slovenia, Spain, Sweden |
Consumption data from these pre‐accession countries are not reported in Table 3 of this opinion; however, they are included in Appendix B for testing purpose.
The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’ in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment’ (EFSA, 2011).
EFSA FEZ Panel (EFSA Panel on Food Enzymes) , Zorn, H. , Baviera, J. M. B. , Bolognesi, C. , Catania, F. , Gadermaier, G. , Greiner, R. , Mayo, B. , Mortensen, A. , Roos, Y. H. , Solano, M. L. M. , Van Loveren, H. , Vernis, L. , Andreoli, C. , Terron, A. , Yurkov, A. , Cavanna, D. , Andryszkiewicz, M. , Kovalkovicova, N. , & Liu, Y. (2026). Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from the non‐genetically modified Aspergillus niger strain AN‐SHGA‐100. EFSA Journal, 24(11), e10404. 10.2903/j.efsa.2026.10404
Adopted: 8 October 2026
Question Number: EFSA‐Q‐2023‐00228
Correspondence: Ask a Question
The declarations of interest of all scientific experts active in EFSA's work are available at https://open.efsa.europa.eu/experts.
See Author contribution section for further description of roles
Notes
Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/1999, Directive 2000/13/EC, Council Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, pp. 7–15.
Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, pp. 1–6.
Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 64, 11.03.2011, pp. 15–24.
Commission Implementing Regulation (EU) No 562/2012 of 27 June 2012 amending Commission Regulation (EU) No 234/2011 with regard to specific data required for risk assessment of food enzymes Text with EEA relevance. OJ L 168, 28.6.2012, p. 21–23.
The full detail is available at the https://www.efsa.europa.eu/en/events/event/ad‐hoc‐meeting‐industry‐association‐amfep‐joint‐dossiers‐food‐enzymes.
Technical dossier/Annex 3.2.1.2.4.b.
Additional data May 2024/Q1.a Annex 1. ANI_fungi AN‐SHGA‐100 report.
Technical dossier/Annex 3.2.1.2.4.c.
Additional data September 2026/ Annex 3.2.1.2.4.f antiSMASH Search Results.
Additional data May 2024/ Q4 3.2.1.2.5.b Manufacturing and Quality Control v2_CONFID.
Additional information May 2024/Annex Q5, Annex Q7c.
Additional data May 2024/Dossier food additive AGL glucoamylase Consolidated 240,520.
Technical dossier/pp. 21‐22/Annex 3.2.1.1.2.3 b.
Technical dossier/p. 24.
Technical dossier/ Annex 3.2.1.1.2.3.a.
Technical dossier/pp. 22–23.
Technical dossier/p. 19/Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.b, Annex 3.2.1.1.2.1.c, Annex 3.2.1.1.2.3.a.
Technical dossier/p. 18/Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.b, Annex 3.2.1.1.2.1.c, Annex 3.2.1.1.2.3.a.
LoQs: Pb = 0.05 mg/kg; Cd, Hg = 0.005 mg/kg each.
Technical dossier/p. 18/Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.b, Annex 3.2.1.1.2.1.c, Annex 3.2.1.1.2.3.a.
Technical dossier/p. 18/Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.b, Annex 3.2.1.1.2.1.c, Annex 3.2.1.1.2.3.a.
Technical dossier/ p. 18/Annex 3.2.1.1.2.1.a, Annex 3.2.1.1.2.1.b, Annex 3.2.1.1.2.1.c, Annex 3.2.1.1.2.3.a.
LoQs: aflatoxin B1 = 0.1 μg/kg, aflatoxin B2 = 0.03 μg/kg, aflatoxin G1 = 0.1 μg/kg, aflatoxin G2 = 0.03 μg/kg, DON = 20 μg/kg, fumonisin B1 = 20 μg/kg, fumonisin B2 = 20 μg/kg, ochratoxin A = 0.2 μg/kg, sterigmatocystin = 10 μg/kg, T2‐toxin = 10 μg/kg, HT2‐toxin = 10 μg/kg, zearalenone = 10 μg/kg.
Additional information September 2026/ Annex 3.2.1.2.4.j.
Technical dossier/Annex 3.2.2.1.1.1.a.
Technical dossier/Annex 3.2.2.1.1.1.b.
Technical dossier/Annex 3.2.2.1.1.2.
Additional information May 2024/Annex Q6a & Annex Q6b.
Additional information May 2024/ Annex Q7a, Annex Q7b & Annex Q7c.
Additional information May 2024/ Annex Q8.
Additional information September 2026/ 3.2.1.5.a FEIM_Glucoamylase CONFID_Consolidated 260,821.
Additional information September 2026/ 3.2.1.5.a FEIM_Glucoamylase CONFID_Consolidated 260,821.
Additional information May 2024/Annex Q11/ p.4.
Additional information May 2024/Annex Q11/ p.5.
Additional information May 2024/Annex Q11/ p.7.
Additional information May 2024/Annex Q11/ p.6.
Additional information May 2024/Annex Q11/ p.1.
Additional information May 2024/Annex Q11/ p.2.
Additional information May 2024/Annex Q11/ p.3.
Version 1.1.1.
REFERENCES
- Armentia, A. , Dias‐Perales, A. , Castrodeza, J. , Dueñas‐Laita, A. , Palacin, A. , & Fernándes, S. (2009). Why can patients with baker's asthma tolerate wheat flour ingestion? Is wheat pollen allergy relevant? Allergologia et Immunopathologia, 37, 203–204. [DOI] [PubMed] [Google Scholar]
- Cullinan, P. , Cook, A. , Jones, M. , Cannon, J. , Fitzgerald, B. , & Newman Taylor, A. J. (1997). Clinical responses to ingested fungal α‐amylase and hemicellulase in persons sensitized to Aspergillus fumigatus? Allergy, 52, 346–349. [DOI] [PubMed] [Google Scholar]
- EFSA (European Food Safety Authority) . (2006). Opinion of the scientific committee related to uncertainties in dietary exposure assessment. EFSA Journal, 5(1), 438. 10.2903/j.efsa.2007.438 [DOI] [Google Scholar]
- EFSA (European Food Safety Authority) . (2009a). Guidance of the scientific committee on transparency in the scientific aspects of risk assessments carried out by EFSA. Part 2: General principles. EFSA Journal, 7(5), 1051. 10.2903/j.efsa.2009.1051 [DOI] [Google Scholar]
- EFSA (European Food Safety Authority) . (2009b). Guidance of EFSA prepared by the scientific panel of food contact material, enzymes, Flavourings and processing aids on the submission of a dossier on food enzymes. EFSA Journal, 7(8), 1305. 10.2903/j.efsa.2009.1305 [DOI] [PMC free article] [PubMed] [Google Scholar]
- EFSA (European Food Safety Authority) . (2011). Use of the EFSA comprehensive European food consumption database in exposure assessment. EFSA Journal, 9(3), 2097. 10.2903/j.efsa.2011.2097 [DOI] [Google Scholar]
- EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes and Processing Aids) . (2019). Statement on the characterisation of microorganisms used for the production of food enzymes. EFSA Journal, 17(6), 5741. 10.2903/j.efsa.2019.5741 [DOI] [PMC free article] [PubMed] [Google Scholar]
- EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes and Processing Aids) , Lambré, C. , Barat Baviera, J. M. , Bolognesi, C. , Cocconcelli, P. S. , Crebelli, R. , Gott, D. M. , Grob, K. , Lampi, E. , Mengelers, M. , Mortensen, A. , Rivière, G. , Steffensen, I.‐L. , Tlustos, C. , Van Loveren, H. , Vernis, L. , Zorn, H. , Glandorf, B. , Herman, L. , … Chesson, A. (2021). Scientific guidance for the submission of dossiers on food enzymes. EFSA Journal, 19(10), 6851. 10.2903/j.efsa.2021.6851 [DOI] [PMC free article] [PubMed] [Google Scholar]
- EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes, Processing Aids) , Lambré, C. , Barat Baviera, J. M. , Bolognesi, C. , Cocconcelli, P. S. , Crebelli, R. , Gott, D. M. , Grob, K. , Lampi, E. , Mengelers, M. , Mortensen, A. , Rivière, G. , Steffensen, I.‐L. , Tlustos, C. , van Loveren, H. , Vernis, L. , Zorn, H. , Roos, Y. , Apergi, K. , … Chesson, A. (2023). Food manufacturing processes and technical data used in the exposure assessment of food enzymes. EFSA Journal, 21(7), 8094. 10.2903/j.efsa.2023.8094 [DOI] [PMC free article] [PubMed] [Google Scholar]
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain) . (2011). Scientific opinion on the risks for public health related to the presence ofzearalenone in food. EFSA Journal, 9(6), 2197. 10.2903/j.efsa.2011.2197 [DOI] [Google Scholar]
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain) , Knutsen, H. K. , Alexander, J. , Barregård, L. , Bignami, M. , Brüschweiler, B. , Ceccatelli, S. , Cottrill, B. , Dinovi, M. , Grasl‐Kraupp, B. , Hogstrand, C. , Hoogenboom, L. R. , Nebbia, C. S. , Oswald, I. P. , Petersen, A. , Rose, M. , Roudot, A. C. , Schwerdtle, T. , Vleminckx, C. , … Edler, L. (2017). Risks to human and animal health related to the presence of deoxynivalenol and its acetylated andmodified forms in food and feed. EFSA Journal, 15(9), 4718. 10.2903/j.efsa.2017.4718 [DOI] [Google Scholar]
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain) , Knutsen, H.‐K. , Barregård, L. , Bignami, M. , Brüschweiler, B. , Ceccatelli, S. , Cottrill, B. , Dinovi, M. , Edler, L. , Grasl‐Kraupp, B. , Hogstrand, C. , Hoogenboom, L. R. , Nebbia, C. S. , Petersen, A. , Rose, M. , Roudot, A.‐C. , Schwerdtle, T. , Vleminckx, C. , Vollmer, G. , … Alexander, J. (2018). Scientific opinion on the appropriateness to set a group health‐based guidance value for fumon‐isins and their modified forms. EFSA Journal, 16(2), 5172. 10.2903/j.efsa.2018.5172 [DOI] [Google Scholar]
- EFSA GMO Panel (EFSA Panel on Genetically Modified Organisms) . (2010). Scientific opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feed. EFSA Journal, 8(7), 1700. 10.2903/j.efsa.2010.1700 [DOI] [PMC free article] [PubMed] [Google Scholar]
- FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization) . (2006). General specifications and considerations for enzyme preparations used in food processing. In Compendium of food additive specifications. 67th meeting (Vol. 3, pp. 63–67). FAO JECFA Monographs. http://www.fao.org/3/a‐a0675e.pdf [Google Scholar]
- Frisvad, J. C. , Møller, L. L. H. , Larsen, T. O. , Kumar, R. , & Arnau, J. (2018). Safety of the fungal workhorses of industrial biotechnology: Update on the mycotoxin and secondary metabolite potential of Aspergillus niger, Aspergillus oryzae, and Trichoderma reesei . Applied Microbiology and Biotechnology, 102, 9481–9515. 10.1007/s00253-018-9354-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kurup, V. P. , Banerjee, B. , Hemmann, S. , Greenberger, P. A. , Blaser, K. , & Crameri, R. (2000). Selected recombinant aspergillus fumigatus allergens bind specifically to IgE in ABPA. Clinical and Experimental Allergy, 30(7), 988–993. 10.1046/j.1365-2222.2000.00837.x [DOI] [PubMed] [Google Scholar]
- OECD (Organisation for Economic Co‐Operation and Development) . (2016). OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 487: In vitro mammalian cell micronucleus test. 29 July 2016. 29 pp. 10.1787/9789264264861-en [DOI]
- OECD (Organisation for Economic Co‐Operation and Development) . (2018). OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 408: Repeated dose 90‐day oral toxicity study in rodents. 27 June 2018. 16 pp. https://www.oecd‐ilibrary.org/docserver/9789264070707‐en.pdf?expires=1660741445&id=id&accname=guest&checksum=96397D93F35C1C4B2EDC61F7C943E708
- OECD (Organisation for Economic Co‐Operation and Development) . (2020). OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 471: Bacterial reverse mutation test. 29 June 2020. 11 pp. https://www.oecd‐ilibrary.org/docserver/9789264071247‐en.pdf?expires=1660741244&id=id&accname=guest&checksum=913CB0A044880B3F24CBF2A547CF413C
- Poulsen, L. K. (2004). Allergy assessment of foods or ingredients derived from biotechnology, gene‐modified organisms, or novel food. Molecular Nutrition & Food Research, 48, 413–423. [DOI] [PubMed] [Google Scholar]
- Shen, H. D. , & Han, S. H. (1998). Characterization of allergens of Penicillium and aspergillus species. Journal of Microbiology, Immunology and Infection, 31, 141–145. [PubMed] [Google Scholar]
- Simonis, B. , Hölzel, C. , & Stark, U. (2014). Glucoamylase: A current allergen in the baking industry. Allergo Journal International, 23 (8), 269–273. 10.1007/s40629-014-0034-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Toyotome, T. , Satoh, M. , Yahiro, M. , Watanabe, A. , Nomura, F. , & Kamei, K. (2014). Glucoamylase is a major allergen of Schizophyllum commune . Clinical and Experimental Allergy, 44, 450–457. [DOI] [PubMed] [Google Scholar]
- Vermani, M. , Kandi‐Vijayan, V. , & Kumar‐Agarwal, M. (2015). Identification of aspergillus (a flavus and a Niger) allergens and heterogeneity of allergic patients' IgE response. Iranian Journal of Allergy, Asthma, and Immunology, 14(4), 361–369. [PubMed] [Google Scholar]
- Xing, H. , Wang, H. , Sun, Y. , & Wang, H. (2022). Recent advances in the allergic cross reactivity between fungi and foods. Journal of Immunology Research, 2022, 1–10. 10.1155/2022/7583400 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
APPENDIX A Dietary exposure estimates to the food enzyme—TOS in details
